Analyst Price Target is $14.33
▲ +1,046.67% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Reviva Pharmaceuticals in the last 3 months. The average price target is $14.33, with a high forecast of $17.00 and a low forecast of $12.00. The average price target represents a 1,046.67% upside from the last price of $1.25.
Current Consensus is
Buy
The current consensus among 5 polled investment analysts is to buy stock in Reviva Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Read More
